Search results
Results from the WOW.Com Content Network
For example, assuming a 99% kill per cycle of chemotherapy, a tumor of 10 11 cells would be reduced to less than one cell with six treatment cycles: 10 11 * 0.01 6 < 1. [3] However, the tumor can also re-grow during the intervals between treatments, limiting the net reduction of each fractional kill. [4]
The SHM that occurs in the germinal center can also target non-immunoglobulin loci and may be responsible for translocation of the BCL-6 gene. BCL-6 genes are involved in several cell processes that can affect the ability of the B-cell to differentiate and proliferate. BCL-6 genes produce BCL-6 proteins.
Subcutaneous panniculitis-like T-cell lymphoma is a rare type of lymphoma that infiltrates the subcutaneous fat but does not involve the skin. There are two subtypes – alpha-beta and gamma-delta. Patients with the gamma-delta subtype have a more aggressive clinical course. [3] It is described as CD3+/CD4-/CD8+, with CD30 and CD56 usually ...
In 2002, a randomized controlled trial showed a higher complete response rate for R-CHOP vs CHOP in elderly patients with Diffuse Large-B-Cell Lymphoma (76% vs 63%). [4] Typically, courses are administered at an interval of two or three weeks (CHOP-14 and CHOP-21 respectively).
Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying Radiation therapy) intended as a first-line treatment for Hodgkin lymphoma.The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens ...
Days 1–4 Prednisolone: 60 mg/m 2: By mouth, twice a day (PO BID) Days 1–5 Oncovin: vincristine: 0.4 mg/m 2: IV continuous infusion over 24 h: Days 1–4 Cyclophosphamide: 750 mg/m 2: IV bolus given over 15 min: Day 5 Hydroxydaunorubicin: doxorubicin: 10 mg/m 2: IV continuous infusion over 24 h: Days 1–4
median overall survival time of approximately 12–16 months, with five-year survival rate of approximately 26% and the long-term survival rate of approximately 4 - 5%. Limited-stage small cell lung carcinoma (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which is small enough to be encompassed within a ...
Dacarbazine, also known as imidazole carboxamide and sold under the brand name DTIC-Dome, is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma. [3] For Hodgkin's lymphoma it is often used together with vinblastine, bleomycin, and doxorubicin. [3] It is given by injection into a vein. [3]